A phase III study of Vectibix (panitumumab) in metastatic colorectal cancer met its primary endpoint of improving overall survival.
As many as 40 percent of patients with lower-risk prostate cancers may be currently receiving overtreatment, according to researchers that examined common treatment practices.
FDA approved Odomzo (sonidegib) capsules for the treatment of patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. Odomzo is marketed by Novartis Pharmaceuticals Corp.
A phase II clinical trial identified patients with a specific molecular subtype of diffuse large B-cell lymphoma that are more likely to respond to Imbruvica (ibrutinib) treatment.
Lenvima (lenvatinib) launched in the U.K. as a treatment option for adult patients with progressive locally advanced or metastatic, differentiated (papillary, follicular, Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Results from the phase III stage of a clinical trial demonstrated that acupuncture-like, transcutaneous electrical nerve stimulation may be equally effective as pilocarpine, the current prescription medication in a pill, to treat radiation-induced dry mouth.
A phase III trial of adjuvant Prolia (denosumab) therapy in postmenopausal women with early hormone receptor positive breast cancer receiving aromatase inhibitor therapy met its primary endpoint of time from randomization to first clinical fracture (HR=0.5, 95 percent CI 0.39-0.65, p<0.0001).
Interim findings from an ongoing phase II clinical study of PEGPH20 showed a doubling of progression-free survival and an improvement trend in overall survival in metastatic pancreatic cancer patients with high levels of hyaluronan.
Progression-free survival data from a phase II study evaluating Afinitor (everolimus) as a second-line therapy in advanced renal cell carcinoma were presented at the annual meeting of the American Society of Clinical Oncology in Chicago.
